Loading
A phase 2 trial of Encorafenib, Cetuximab, Pembrolizumab in colorectal cancer, run by Pfizer, active and no longer recruiting.
A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal Cancer is a phase 2 interventional study registered as NCT05217446 by Pfizer, with 108 participants enrolled, started 2022-07-11 and due to reach its primary completion in 2026-06-19. Interventions recorded: Encorafenib, Cetuximab, Pembrolizumab. Conditions listed: Metastatic Colorectal Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Encorafenib, BRAF V600E-mutant colorectal cancer, Cetuximab, Monoclonal antibodies.
Shares Mismatch-repair deficient (MSI-high) colorectal cancer, Cetuximab, Pembrolizumab, Colorectal cancer.
Shares Encorafenib, BRAF V600E-mutant colorectal cancer, Cetuximab, Monoclonal antibodies.
Shares BRAF V600E-mutant colorectal cancer, Cetuximab, Monoclonal antibodies, Small-molecule kinase inhibitors.
Shares Encorafenib, Cetuximab, Monoclonal antibodies, Small-molecule kinase inhibitors.
Shares Mismatch-repair deficient (MSI-high) colorectal cancer, Pembrolizumab, Colorectal cancer, Immune checkpoint inhibitors.
Shares Encorafenib, BRAF V600E-mutant colorectal cancer, Small-molecule kinase inhibitors.
Shares Mismatch-repair deficient (MSI-high) colorectal cancer, Pembrolizumab, Colorectal cancer, Immune checkpoint inhibitors.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/